# US 2024/0252671 A1 · Neodegrader-anti-cd33 antibody conjugates

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0252671 A1
- Document ID: US20240252671A1
- Status: Published application
- Kind: A1
- Application number: 18/566,805
- Filed: 2022-06-02
- Published: 2024-08-01
- Earliest claimed: 2021-06-03
- Assignees: Orum Therapeutics Inc.
- Applicants: Orum Therapeutics, Inc.
- Inventors: Nathan FISHKIN; Peter U. PARK; Chen BAI
- Web page: https://patentgrep.com/patent/US20240252671A1

## CPC

- A61K 47/6803: {Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/6849: {the antibody targeting a receptor, a cell surface antigen or a cell surface determinant}
- A61K 47/6867: {the tumour determinant being from a cell of a blood cancer}
- A61K 47/6889: {Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment}
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure provides neoDegraders conjugated to anti-CD33 antibodies. Also provided are compositions comprising the conjugates. The compounds and compositions are useful for treating a disease or condition, e.g., cancer, in a subject in need thereof.

## Claims

### Claim 1

A conjugate of formula (I):
or a pharmaceutically acceptable salt thereof, wherein:
a is an integer from 1 to 10;
A is phenyl or a C4-C10cycloalkyl ring;
U is selected from NH and CF2;
R1 is independently selected from hydrogen and halo;
X is selected from —NR2—, ═C(CH3)—, -Q-(CH2)n—, and -Q(CH2)mQ′(CH2)n—; wherein
Q and Q′ are each independently O, S, or N(R2)v;
v is 1 or 2;
each R2 is independently hydrogen or C1-C6alkyl;
n is an integer from 1 to 6; and
m is an integer from 2 to 6;
wherein the left side of each group is attached to L and the right side is attached to A;
provided that when X is NH or -Q-(CH2)n—, R1 is halo;
L is a cleavable linker or non-cleavable linker; and
Bm is an anti-CD33 antibody or antigen-binding portion thereof comprising a heavy chain variable region (VH) complementarity determining region (CDR) 1 (VH-CDR1) comprising the amino acid sequence as set forth in SEQ ID NO: 1, a VH-CDR2 comprising the amino acid sequence as set forth in SEQ ID NO: 2, a VH-CDR3 comprising the amino acid sequence as set forth in SEQ ID NO: 3, a light chain variable region (VL) CDR1 (VL-CDR1) comprising the amino acid sequence as set forth in SEQ ID NO: 5, a VL-CDR2 comprising the amino acid sequence as set forth in SEQ ID NO: 6, and a VL-CDR3 comprising the amino acid sequence as set forth in SEQ ID NO: 7.

### Claim 2 (depends on 1)

The conjugate of claim 1, wherein the anti-CD33 antibody or antigen-binding portion thereof comprises a VH comprising the amino acid sequence set forth in SEQ ID NO: 4 and a VL comprising the amino acid sequence as set forth in SEQ ID NO: 8.

### Claim 3 (depends on 1, 2)

The conjugate of claim 1 or 2, wherein the anti-CD33 antibody or antigen-binding portion thereof comprises a constant region, wherein the constant region comprises at least one amino acid different from Gemtuzumab.

### Claim 4 (depends on 1, 2, 3)

The conjugate of any one of claims 1 to 3, wherein the anti-CD33 antibody or antigen-binding portion thereof is an IgG1 antibody or antigen-binding portion thereof.

### Claim 5 (depends on 1, 2, 3, 4)

The conjugate of any one of claims 1 to 4, wherein the anti-CD33 antibody or antigen-binding portion thereof comprises alanine at amino acid 297 corresponding to the constant region.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The conjugate of any one of claims 1 to 5, wherein the anti-CD33 antibody comprises a heavy chain as set forth in SEQ ID NO: 9 and a light chain as set forth in SEQ ID NO: 10.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The conjugate of any one of claims 1 to 6, or a pharmaceutically acceptable salt thereof, wherein a is an integer from 2 to 8.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The conjugate of any one of claims 1 to 7, or a pharmaceutically acceptable salt thereof, wherein L is a non-cleavable linker.

### Claim 9 (depends on 8)

The conjugate of claim 8, or a pharmaceutically acceptable salt thereof, wherein L is selected from the group consisting of
wherein:
p is an integer from 1 to 10;
is the point of attachment to X; and
is the point attachment to the anti-CD33 antibody or antigen-binding portion thereof.

### Claim 10 (depends on 9)

The conjugate of claim 9, or a pharmaceutically acceptable salt thereof, wherein L is

### Claim 11 (depends on 9, 10)

The conjugate of claim 9 or 10, or a pharmaceutically acceptable salt thereof, wherein p is 5.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7)

The conjugate of any one of claims 1 to 7, or a pharmaceutically acceptable salt thereof, wherein L is a cleavable linker.

### Claim 13 (depends on 12)

The conjugate of claim 12, or a pharmaceutically acceptable salt thereof, wherein the cleavable linker is cleavable by a protease.

### Claim 14 (depends on 12, 13)

The conjugate of claim 12 or 13, or a pharmaceutically acceptable salt thereof, wherein L is selected from the group consisting of
wherein:
q is an integer from 2 to 10;
Z1, Z2, Z3, and Z4 are each independently absent or a naturally-occurring amino acid residue in the L- or D-configuration, provided that at least two of Z, Z2, Z3, and Z4 are amino acid residues;
is the point of attachment to X; and
is the point of attachment to the anti-CD33 antibody or antigen-binding portion thereof.

### Claim 15 (depends on 14)

The conjugate of claim 14, or a pharmaceutically acceptable salt thereof, wherein Z1, Z2, Z3, and Z4 are independently absent or selected from the group consisting of L-valine, D-valine, L-citrulline, D-citrulline, L-alanine, D-alanine, L-glutamine, D-glutamine, L-glutamic acid, D-glutamic acid, L-aspartic acid, D-aspartic acid, L-asparagine, D-asparagine, L-phenylalanine, D-phenylalanine, L-lysine, D-lysine, and glycine; provided that at least two of Z1, Z2, Z3, and Z4 are amino acid residues.

### Claim 16 (depends on 15)

The conjugate of claim 15, or a pharmaceutically acceptable salt thereof, wherein:
Z1 is absent or glycine;
Z2 is absent or selected from the group consisting of L-glutamine, D-glutamine, L-glutamic acid, D-glutamic acid, L-aspartic acid, D-aspartic acid, L-alanine, D-alanine, and glycine;
Z3 is selected from the group consisting of L-valine, D-valine, L-alanine, D-alanine, L-phenylalanine, D-phenylalanine, and glycine; and
Z4 is selected from the group consisting of L-alanine, D-alanine, L-citrulline, D-citrulline, L-asparagine, D-asparagine, L-lysine, D-lysine, L-phenylalamine, D-phenylalanine, and glycine.

### Claim 17 (depends on 14)

The conjugate of claim 14, or a pharmaceutically acceptable salt thereof, wherein L is

### Claim 18 (depends on 17)

The conjugate of claim 17, or a pharmaceutically acceptable salt thereof, wherein q is 5.

### Claim 19 (depends on 12)

The conjugate of claim 12, or a pharmaceutically acceptable salt thereof, wherein L is a bioreducible linker.

### Claim 20 (depends on 12, 19)

The conjugate of claim 12 or 19, wherein L is selected from the group consisting of
wherein:
q is an integer from 2 to 10;
R, R′, R″, and R′″ are each independently selected from hydrogen, C1-C6alkoxyC1-C6alkyl, (C1-C6)2NC1-C6alkyl, and C1-C6alkyl, or, two geminal R groups, together with the carbon atom to which they are attached, can form a cyclobutyl or cyclopropyl ring;
is the point of attachment to X; and
is the point of attachment to the anti-CD33 antibody or antigen-binding portion thereof.

### Claim 21 (depends on 12)

The conjugate of claim 12, or a pharmaceutically acceptable salt thereof, wherein L is an acid cleavable linker.

### Claim 22 (depends on 12, 21)

The conjugate of claim 12 or 21, or a pharmaceutically acceptable salt thereof, wherein L is selected from the group consisting of
wherein:
q is an integer from 2 to 10;
is the point of attachment to X; and
is the point of attachment to the anti-CD33 antibody or antigen-binding portion thereof.

### Claim 23 (depends on 12)

The conjugate of claim 12, or a pharmaceutically acceptable salt thereof, wherein L is a click-to-release linker.

### Claim 24 (depends on 12, 23)

The conjugate of claim 12 or 23, or a pharmaceutically acceptable salt thereof, wherein L is selected from
wherein:
q is an integer from 2 to 10;
is the point of attachment to X; and
the point of attachment to the anti-CD33 antibody or antigen-binding portion thereof.

### Claim 25 (depends on 12)

The conjugate of claim 12, or a pharmaceutically acceptable salt thereof, wherein L is a pyrophosphatase cleavable linker.

### Claim 26 (depends on 25)

The conjugate of claim 25, or a pharmaceutically acceptable salt thereof, wherein L is
wherein:
q is an integer from 2 to 10;
is the point of attachment to X; and
is the point of attachment to the anti-CD33 antibody or antigen-binding portion thereof.

### Claim 27 (depends on 12)

The conjugate of claim 12, or a pharmaceutically acceptable salt thereof, wherein L is a beta-glucuronidase cleavable linker.

### Claim 28 (depends on 12, 27)

The conjugate of claim 12 or 27, or a pharmaceutically acceptable salt thereof, wherein L is selected from
wherein:
q is an integer from 2 to 10;
---- is absent or a bond;
is the point of attachment to X; and
is the point of attachment to the anti-CD33 antibody or antigen-binding portion thereof.

### Claim 29 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

The conjugate of any one of claims 1 to 28, or a pharmaceutically acceptable salt thereof, wherein:
A is phenyl;
U is NH;
R1 is halo; and
X is —N(R2)v(CH2)mO(CH2)n—; wherein:
v is 1;
m and n are 2; and
R2 is methyl.

### Claim 30 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

The conjugate of any one of claims 1 to 28, wherein:
A is phenyl;
U is NH;
R1 is halo; and
X is —N(R2)v(CH2)mO(CH2)n—; wherein:
v is 2;
m and n are 2; and
each R2 is methyl.

### Claim 31 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

The conjugate of any one of claims 1 to 28, wherein:
A is phenyl;
U is NH;
R1 is halo; and
X is —O(CH2)n—; wherein:
n is 2.

### Claim 32 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

The conjugate of any one of claims 1 to 28, wherein:
A is phenyl;
U is NH;
R1 is halo; and
X is —S(CH2)n—; wherein:
n is 2.

### Claim 33 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

The conjugate of any one of claims 1 to 28, wherein:
A is phenyl;
U is NH;
R1 is hydrogen; and
X is —NR2—; wherein:
R2 is methyl.

### Claim 34 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

The conjugate of any one of claims 1 to 28, wherein:
A is phenyl;
U is NH;
R1 is halo; and
X is —NR2—; wherein:
R2 is hydrogen.

### Claim 35 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

The conjugate of any one of claims 1 to 28, wherein:
A is phenyl;
U is NH;
R1 is hydrogen; and
X is —C(CH3)═.

### Claim 36 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

The conjugate of any one of claims 1 to 28, wherein:
A is a C4-C10cycloalkyl ring;
U is NH;
R1 is hydrogen; and
X is —N(R2)(CH2)mO(CH2)n—; wherein:
n is 1;
m is 2; and
R2 is methyl.

### Claim 37

A conjugate of formula (V):
or a pharmaceutically acceptable salt thereof, wherein Bm is an anti-CD33 antibody or antigen-binding portion thereof comprising a VH-CDR1 comprising the amino acid sequence as set forth in SEQ ID NO: 1, a VH-CDR2 comprising the amino acid sequence as set forth in SEQ ID NO: 2, a VH-CDR3 comprising the amino acid sequence as set forth in SEQ ID NO: 3, a VL-CDR1 comprising the amino acid sequence as set forth in SEQ ID NO: 5, a VL-CDR2 comprising the amino acid sequence as set forth in SEQ ID NO: 6, and a VL-CDR3 comprising the amino acid sequence as set forth in SEQ ID NO: 7.

### Claim 38

A conjugate of formula (VI):
or a pharmaceutically acceptable salt thereof, wherein Bm is an anti-CD33 antibody or antigen-binding portion thereof comprising a VH-CDR1 comprising the amino acid sequence as set forth in SEQ ID NO: 1, a VH-CDR2 comprising the amino acid sequence as set forth in SEQ ID NO: 2, a VH-CDR3 comprising the amino acid sequence as set forth in SEQ ID NO: 3, a VL-CDR1 comprising the amino acid sequence as set forth in SEQ ID NO: 5, a VL-CDR2 comprising the amino acid sequence as set forth in SEQ ID NO: 6, and a VL-CDR3 comprising the amino acid sequence as set forth in SEQ ID NO: 7.

### Claim 39

A conjugate of formula (VII):
or a pharmaceutically acceptable salt thereof, wherein Bm is an anti-CD33 antibody or antigen-binding portion thereof comprising a VH-CDR1 comprising the amino acid sequence as set forth in SEQ ID NO: 1, a VH-CDR2 comprising the amino acid sequence as set forth in SEQ ID NO: 2, a VH-CDR3 comprising the amino acid sequence as set forth in SEQ ID NO: 3, a VL-CDR1 comprising the amino acid sequence as set forth in SEQ ID NO: 5, a VL-CDR2 comprising the amino acid sequence as set forth in SEQ ID NO: 6, and a VL-CDR3 comprising the amino acid sequence as set forth in SEQ ID NO: 7.

### Claim 40 (depends on 37, 38, 39)

The conjugate of any one of claims 37-39 or a pharmaceutically acceptable salt thereof, wherein the anti-CD33 antibody or antigen-binding portion thereof comprises (i) a VH comprising the amino acid sequence as set forth in SEQ ID NO: 4 and a VL comprising the amino acid sequence as set forth in SEQ ID NO: 8 or (ii) a heavy chain comprising the amino acid sequence as set forth in SEQ ID NO: 9 and a light chain comprising the amino acid sequence as set forth in SEQ ID NO: 10.

### Claim 41 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40)

A pharmaceutical composition comprising a conjugate or compound of any one of claims 1 to 40, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers.

### Claim 42 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41)

A method of treating cancer in a subject in need thereof, the method comprising administering to the subject a pharmaceutically acceptable amount of a conjugate or composition of any of claims 1 to 41, or a pharmaceutically acceptable salt thereof.

### Claim 43 (depends on 42)

The method of claim 42, wherein the cancer is a hematological/blood cancer.

### Claim 44 (depends on 42)

The method of claim 42, wherein the cancer is a multiple myeloma, leukemia, malignant lymphoma, Hodgkin's disease, or chronic myeloproliferative disease.

### Claim 45 (depends on 42)

The method of claim 42, wherein the cancer is acute myeloid leukemia or lymphoma.

### Claim 46 (depends on 42)

The method of claim 42, wherein the cancer is acute myeloid leukemia.

### Claim 47 (depends on 42, 43, 44, 45, 46)

The method of any one of claims 42-46, wherein the cancer is resistant or refractory to Mylotarg.

### Claim 48 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41)

A method of treating myelodysplastic syndrome in a subject in need thereof, the method comprising administering to the subject a pharmaceutically acceptable amount of a conjugate or composition of any of claims 1 to 41, or a pharmaceutically acceptable salt thereof.

### Claim 49 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 42, 43, 44, 45, 46, 47, 48)

The method of any one of claims 42 to 48, further comprising administering to the subject a pharmaceutically acceptable amount of an additional agent prior to, after, or simultaneously with the conjugate of any one of claims 1 to 40, or a pharmaceutically acceptable salt thereof.

### Claim 50 (depends on 49)

The method of claim 49, wherein the additional agent is a cytotoxic agent or an immune response modifier.

### Claim 51 (depends on 50)

The method of claim 50, wherein the immune response modifier is a checkpoint inhibitor.

### Claim 52 (depends on 51)

The method of claim 51 wherein the checkpoint inhibitor comprises a PD-1 inhibitor, a PD-L1 inhibitor, a CTLA-4 inhibitor, a TIM3 inhibitor, and/or a LAG-3 inhibitor.

### Claim 53 (depends on 1)

A method of preparing the conjugate of claim 1, or a pharmaceutically acceptable salt thereof, the process comprising reacting an anti-CD33 antibody or antigen-binding portion thereof with a compound of formula (I-1):
or a pharmaceutically acceptable salt thereof, wherein:
a is an integer from 1 to 10;
A is phenyl or a C4-C10cycloalkyl ring;
R1 is independently selected from hydrogen and halo;
U is selected from NH and CF2;
X is selected from —N(R2)v—, ═C(CH3)—, -Q-(CH2)n—, and -Q(CH2)mQ′(CH2)n—; wherein
v is 1 or 2;
Q and Q′ are each independently O, S, or NR2;
each R2 is independently hydrogen or C1-C6alkyl;
n is an integer from 1 to 6; and
m is an integer from 2 to 6;
wherein the left side of each group is attached to L′ and the right side is attached to A;
provided that when X is NH or -Q-(CH2)n—, R1 is halo;
L′ is a cleavable or non-cleavable linker precursor that conjugates to the anti-CD33 antibody or antigen-binding portion thereof, wherein the anti-CD33 antibody or antigen-binding portion thereof comprises a VH-CDR1 comprising the amino acid sequence as set forth in SEQ ID NO: 1, a VH-CDR2 comprising the amino acid sequence as set forth in SEQ ID NO: 2, a VH-CDR3 comprising the amino acid sequence as set forth in SEQ ID NO: 3, a light chain variable region (VL) CDR1 comprising the amino acid sequence as set forth in SEQ ID NO: 5, a VL-CDR2 comprising the amino acid sequence as set forth in SEQ ID NO: 6, and a VL-CDR3 comprising the amino acid sequence as set forth in SEQ ID NO: 7.

### Claim 54 (depends on 53)

The method of claim 53, wherein the anti-CD33 antibody or antigen-binding portion thereof comprises a VH comprising the amino acid sequence as set forth in SEQ ID NO: 4 and a VL comprising the amino acid sequence as set forth in SEQ ID NO: 8.

### Claim 55 (depends on 53, 54)

The method of claim 53 or 54, wherein the anti-CD33 antibody or antigen-binding portion thereof comprises a constant region, wherein the constant region comprises at least one amino acid different from Gemtuzumab.

### Claim 56 (depends on 53, 54, 55)

The method of any one of claims 53 to 55, wherein the anti-CD33 antibody or antigen-binding portion thereof is an IgG1 antibody or antigen-binding portion thereof.

### Claim 57 (depends on 53, 54, 55, 56)

The method of any one of claims 53 to 56, wherein the anti-CD33 antibody or antigen-binding portion thereof comprises alanine at amino acid 297 corresponding to the constant region.

### Claim 58 (depends on 53, 57)

The method of any one of claim 53 or 57, wherein the anti-CD33 antibody comprises a heavy chain as set forth in SEQ ID NO: 9 and a light chain as set forth in SEQ ID NO: 10.

### Claim 59 (depends on 53, 54, 55, 56, 57, 58)

The method of any one of claims 53 to 58, further comprising reducing the anti-CD33 antibody or antigen-binding portion thereof prior to reacting with the compound of formula (I-1).

### Claim 60 (depends on 53, 54, 55, 56, 57, 58, 59)

The method of any one of claims 53 to 59, wherein a is an integer from 2 to 8.

### Claim 61 (depends on 53, 54, 55, 56, 57, 58, 59, 60)

The method of any one of claims 53 to 60, wherein L′ is a non-cleavable linker precursor, a cleavable linker precursor, a bioreducible linker precursor, an acid cleavable linker precursor, a click-to-release linker precursor, a pyrophosphatase cleavable linker precursor, a beta-glucoronidase cleavable linker precursor, or any combination thereof.
